CAJ | 학술논문

目的：探讨索拉非尼联合顺铂对肺癌 A549细胞裸鼠移植瘤的抑制作用及其毒性作用。方法将肺癌A549细胞移植瘤裸鼠随机分为5组：空白对照组、溶剂对照组、索拉非尼组、顺铂组和联合用药组，分别给予处理。观察各组裸鼠肿瘤大体形态，测定裸鼠体重、肿瘤大小，计算瘤重、完全缓解（CR）、部分缓解（PR）、T2（治疗后肿瘤增长至治疗前瘤体积2倍所需的时间）和肿瘤生长延迟时间（ TGD），记录动物死亡率。结果联合用药组疗效优于索拉非尼及顺铂单药组。治疗后第30天联合用药组瘤重小于对照组及索拉非尼和顺铂单药组（ P＜0．01）。死亡率均未超过20％，治疗后体重减轻亦未超过20％。溶剂对照组、顺铂组、索拉非尼组及联合用药组各死亡1只。各组未出现CR，其中索拉非尼单药组及联合用药组PR各1例。索拉非尼单药组和顺铂单药组TGD分别为8．53天和9．72天，联合用药组的TGD达16．73天。结论索拉非尼及顺铂单药对人肺癌A549裸鼠移植瘤模型均有抑制作用，联合用药增强抗肿瘤效应。两药联合具有较好的安全性和耐受性。
목적：탐토색랍비니연합순박대폐암 A549세포라서이식류적억제작용급기독성작용。방법장폐암A549세포이식류라서수궤분위5조：공백대조조、용제대조조、색랍비니조、순박조화연합용약조，분별급여처리。관찰각조라서종류대체형태，측정라서체중、종류대소，계산류중、완전완해（CR）、부분완해（PR）、T2（치료후종류증장지치료전류체적2배소수적시간）화종류생장연지시간（ TGD），기록동물사망솔。결과연합용약조료효우우색랍비니급순박단약조。치료후제30천연합용약조류중소우대조조급색랍비니화순박단약조（ P＜0．01）。사망솔균미초과20％，치료후체중감경역미초과20％。용제대조조、순박조、색랍비니조급연합용약조각사망1지。각조미출현CR，기중색랍비니단약조급연합용약조PR각1례。색랍비니단약조화순박단약조TGD분별위8．53천화9．72천，연합용약조적TGD체16．73천。결론색랍비니급순박단약대인폐암A549라서이식류모형균유억제작용，연합용약증강항종류효응。량약연합구유교호적안전성화내수성。
Objective To study the inhibitive effect and side effects of sorafenib combined with cisplatin ( DDP ) on NSCLC cells A549.Methods A549 NSCLC xenograft models were divided into 5 groups:blank control group,vehicle control group,Sorafenib-treated group,DDP-treated group and combination treatment group .The general morphology of nude mice tumor was observed,weight of nude mice,tumor size and weight were recorded.Complete remission,parital remission,T2(The time re-quired for tumor to double its size after treatment ),tumor growth delay(TGD)and mortality rate were recorded.Results The combination treatment group was more effective than Sorafenib and DDP alone group ,and tumor weight of the combination treat-ment group was lower than that of the control group and Sorafenib and DDP alone group after 30-day treatment .The mortality rate and weight loss were less than 20%.1 mouse died during the treatment in the vehicle group , DDP-treated group , combination treatment group and Sorafenib-treated group ,respectively .No CR was observed and 1 PR occured in the Sorafenib-treated group and the combination treatment group ,respectively.TGD of the combination group was 16.73 d,which was longer than that of Sor-afenib(8.53 d)or DDP(9.72 d)alone group.Conclusion Sorafenib and DDP alone both have inhibitive effect towards A 549 NSCLC tumor xenografts ,and combination of Sorafenib with DDP can enhance antitumor effect with preferable safety and tolerabil -ity.